As of close of business last night, Pieris Pharmaceuticals Inc’s stock clocked out at $0.19, up 2.07% from its previous closing price of $0.18. In other words, the price has increased by $+0.0038 from its previous closing price. On the day, 698710 shares were traded.
Ratios:
To gain a deeper understanding of PIRS’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.24 and its Current Ratio is at 3.24. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
On May 14, 2019, Robert W. Baird started tracking the stock assigning a Outperform rating and target price of $5.Robert W. Baird initiated its Outperform rating on May 14, 2019, with a $5 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on May 25 ’23 when KIRITSY CHRISTOPHER P bought 10,000 shares for $0.85 per share. The transaction valued at 8,500 led to the insider holds 20,000 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PIRS now has a Market Capitalization of 18.29M and an Enterprise Value of -14.23M. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.43 while its Price-to-Book (P/B) ratio in mrq is 0.69. Its current Enterprise Value per Revenue stands at -0.30 whereas that against EBITDA is 1.16.
Stock Price History:
Over the past 52 weeks, PIRS has reached a high of $1.29, while it has fallen to a 52-week low of $0.14. The 50-Day Moving Average of the stock is 0.1739, while the 200-Day Moving Average is calculated to be 0.2405.
Shares Statistics:
It appears that PIRS traded 590.27K shares on average per day over the past three months and 1.95M shares per day over the past ten days. A total of 98.94M shares are outstanding, with a floating share count of 91.49M. Insiders hold about 7.45% of the company’s shares, while institutions hold 38.97% stake in the company. Shares short for PIRS as of Mar 15, 2024 were 41.57k with a Short Ratio of 0.07, compared to 66.22k on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 0.04% and a Short% of Float of 0.04%.
Earnings Estimates
As of right now, 1 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of -$0.12 for the current quarter, with a high estimate of -$0.12 and a low estimate of -$0.12, while EPS last year was -$0.11. The consensus estimate for the next quarter is $0, with high estimates of $0 and low estimates of $0.
Analysts are recommending an EPS of between -$0.35 and -$0.35 for the fiscal current year, implying an average EPS of -$0.35. EPS for the following year is $0, with 0 analysts recommending between $0 and $0.
Revenue Estimates
In the current quarter, 1 analysts expect revenue to total $1.3M. It ranges from a high estimate of $2.24M to a low estimate of $2.24M. As of the current estimate, Pieris Pharmaceuticals Inc’s year-ago sales were $5.85M, an estimated decrease of -77.80% from the year-ago figure. For the next quarter, 1 analysts are estimating revenue of $2.24M, a decrease of -65.50% over than the figure of -$77.80% in the same quarter last year. There is a high estimate of $2.24M for the next quarter, whereas the lowest estimate is $2.24M.
A total of 1 analysts have provided revenue estimates for PIRS’s current fiscal year. The highest revenue estimate was $31.98M, while the lowest revenue estimate was $31.98M, resulting in an average revenue estimate of $42.81M. In the same quarter a year ago, actual revenue was $25.9M, up 65.30% from the average estimate. Based on 1 analysts’ estimates, the company’s revenue will be $6.62M in the next fiscal year. The high estimate is $6.62M and the low estimate is $6.62M. The average revenue growth estimate for next year is down -84.50% from the average revenue estimate for this year.
